Effectiveness and safety of infliximab in rheumatoid arthritis: Analysis from a canadian multicenter prospective observational registry

Arthritis Care and Research

Volumn 66, Issue 8, 2014, Pages 1142-1151

  Thorne, Carter ^a,j   Bensen, William G ^b   Choquette, Denis ^c   Chow, Andrew ^d   Khraishi, Majed ^e   Atkins, Christopher J ^f   Kelsall, John T ^g   Lehman, Allen J ^h   Shawi, May ^h   Khalil, Hayssam ^h   Nantel, Francois ^h   Rampakakis, Emmanouil ^i,k   Sampalis, John S ^i,l   Otawa, Susan ^h  

^a SOUTHLAKE REGIONAL HEALTH CENTRE   (Canada)

^b ST JOSEPH S HOSPITAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d Credit Valley Rheumatology   (Canada)

^e MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^f UNIVERSITY OF VICTORIA   (Canada)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h Janssen Inc   (Canada)

ⁱ JSS Medical Research   (Canada)

^j Novartis   (Canada)

^k UNIVERSITY OF TORONTO   (Canada)

^l MCGILL UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLIMUMAB; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTHRALGIA; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BACKACHE; BRONCHITIS; CLINICAL DISEASE ACTIVITY INDEX; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE DURATION; DIZZINESS; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; GANGRENE; HEALTH ASSESSMENT QUESTIONNAIRE; HEART ATRIUM FIBRILLATION; HUMAN; HYPOTENSION; IMMUNOTHERAPY; INCIDENCE; INFUSION RELATED REACTION; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MILIARY TUBERCULOSIS; MULTICENTER STUDY (TOPIC); NAUSEA; OUTCOME ASSESSMENT; PAIN; PATIENT ASSESSMENT; PATIENT CARE; PRURITUS; RASH; REMISSION; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIMPLIFIED DISEASE ACTIVITY INDEX; UPPER RESPIRATORY TRACT INFECTION; URTICARIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CANADA; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES; TREATMENT OUTCOME;

EID: 84904976122     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22290     Document Type: Article

References (24)

1. Smolen Js, Aletaha D, Le Bars M, Poncet C, Schiff M, Kremer JM, et al. A significant proportion of patients with RA achieve Simplified Disease Activity Index (SDAI)-defined low disease activity or remission with abatacept vs placebo, and SDAI remission is associated with reduced radiographic progression [abstract]. Arthritis Rheum 2009; 60 Suppl: S633.
2. Smolen JS, Han C, van der Heijde DM, Emery P, Bathon JM, Keystone E, et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and TNF-blockade. Ann Rheum Dis 2009; 68: 823-7.
3. Bykerk VP, Akhavan P, Hazlewood GS, Schieir O, Dooley A, Haraoui B, et al. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol 2012; 39: 1559-82.
4. Kobelt G,. Thoughts on health economics in rheumatoid arthritis. Ann Rheum Dis 2007; 66 Suppl 3: iii35-9.
5. Arthritis Alliance of Canada. The impact of arthritis in Canada: today and over the next 30 years. Toronto: Arthritis Alliance of Canada; 2011.
6. Haraoui B,. The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis. J Rheumatol Suppl 2005; 72: 46-7.
7. Brennan FM, Maini RN, Feldmann M,. TNF alpha: a pivotal role in rheumatoid arthritis? Br J Rheumatol 1992; 31: 293-8.
8. Scott DL, Kingsley GH,. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006; 355: 704-12.
9. Smolen JS, Emery P,. Infliximab: 12 years of experience. Arthritis Res Ther 2011; 25:13 Suppl 1: S2.
10. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009; 4: CD007848.
11. Gulfe A, Aletaha D, Saxne T, Geborek P,. Disease activity level, remission and response in established rheumatoid arthritis: performance of various criteria sets in an observational cohort, treated with anti-TNF agents. BMC Musculoskelet Disord 2009; 10: 41.
12. Sampalis J,. Post-marketing observational studies: providing insight into real-life clinical practice regarding safety, efficacy and patients' drug compliance. Bioscienceworld; 2006. URL: http://www.bioscienceworld.ca/ APracticalGuideToPostMarketingObservationalStudiesPMOS.
13. Sampalis J,. A practical guide to post-marketing observational studies (PMOS). Bioscienceworld; 2008. URL: http://www.bioscienceworld.ca/ APracticalGuideToPostMarketingObservationalStudiesPMOS.
14. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
15. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA,. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993; 20: 557-60.
16. Curtis JR, Jain A, Askling J, Bridges SL Jr, Carmona L, Dixon W, et al. A comparison of patient characteristics and outcomes in selected European and US rheumatoid arthritis registries. Semin Arthritis Rheum 2010; 40: 2-14.e1.
17. Pease C, Pope JE, Truong D, Bombardier C, Widdifield J, Thorne JC, et al. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy. Semin Arthritis Rheum 2011; 41: 81-9.
18. Soderlin MK, Geborek P,. Changing pattern in the prescription of biological treatment in rheumatoid arthritis: a 7-year follow-up of 1839 patients in Southern Sweden. Ann Rheum Dis 2008; 67: 37-42.
19. DeWitt EM, Glick HA, Albert DA, Joffe MM, Wolfe F,. Medicare coverage of tumor necrosis factor α inhibitors as an influence on physicians' prescribing behavior. Arch Intern Med 2006; 166: 57-63.
20. Mierau M, Schoels M, Gonda G, Fuchs J, Aletaha D, Smolen JS,. Assessing remission in clinical practice. Rheumatology (Oxford) 2007; 46: 975-9.
21. Balsa A, de Miguel E, Castillo C, Peiteado D, Martin-Mola E,. Superiority of SDAI over DAS-28 in assessment of remission in rheumatoid arthritis patients using power Doppler ultrasonography as a gold standard. Rheumatology (Oxford) 2010; 49: 683-90.
22. Keystone E, Freundlich B, Schiff M, Li J, Hooper M,. Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA. J Rheumatol 2009; 36: 522-31.
23. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52: 3381-90.
24. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN,. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2006; 33: 2398-408.